Vital Signs: Health Disparities in Hemodialysis-Associated Staphylococcus aureus Bloodstream Infections - United States, 2017-2020.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
10 Feb 2023
Historique:
entrez: 9 2 2023
pubmed: 10 2 2023
medline: 14 2 2023
Statut: epublish

Résumé

Racial and ethnic minorities are disproportionately affected by end-stage kidney disease (ESKD). ESKD patients on dialysis are at increased risk for Staphylococcus aureus bloodstream infections, but racial, ethnic, and socioeconomic disparities associated with this outcome are not well described. Surveillance data from the 2020 National Healthcare Safety Network (NHSN) and the 2017-2020 Emerging Infections Program (EIP) were used to describe bloodstream infections among patients on hemodialysis (hemodialysis patients) and were linked to population-based data sources (CDC/Agency for Toxic Substances and Disease Registry [ATSDR] Social Vulnerability Index [SVI], United States Renal Data System [USRDS], and U.S. Census Bureau) to examine associations with race, ethnicity, and social determinants of health. In 2020, 4,840 dialysis facilities reported 14,822 bloodstream infections to NHSN; 34.2% were attributable to S. aureus. Among seven EIP sites, the S. aureus bloodstream infection rate during 2017-2020 was 100 times higher among hemodialysis patients (4,248 of 100,000 person-years) than among adults not on hemodialysis (42 of 100,000 person-years). Unadjusted S. aureus bloodstream infection rates were highest among non-Hispanic Black or African American (Black) and Hispanic or Latino (Hispanic) hemodialysis patients. Vascular access via central venous catheter was strongly associated with S. aureus bloodstream infections (NHSN: adjusted rate ratio [aRR] = 6.2; 95% CI = 5.7-6.7 versus fistula; EIP: aRR = 4.3; 95% CI = 3.9-4.8 versus fistula or graft). Adjusting for EIP site of residence, sex, and vascular access type, S. aureus bloodstream infection risk in EIP was highest in Hispanic patients (aRR = 1.4; 95% CI = 1.2-1.7 versus non-Hispanic White [White] patients), and patients aged 18-49 years (aRR = 1.7; 95% CI = 1.5-1.9 versus patients aged ≥65 years). Areas with higher poverty levels, crowding, and lower education levels accounted for disproportionately higher proportions of hemodialysis-associated S. aureus bloodstream infections. Disparities exist in hemodialysis-associated S. aureus infections. Health care providers and public health professionals should prioritize prevention and optimized treatment of ESKD, identify and address barriers to lower-risk vascular access placement, and implement established best practices to prevent bloodstream infections.

Identifiants

pubmed: 36757874
doi: 10.15585/mmwr.mm7206e1
pmc: PMC9925139
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153-159

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Jennifer Ahern reports a grant from the National Institute of Health and receipt of a Chan Zuckerberg Biohub Investigators Program gift. Lee H. Harrison reports meeting and travel support from Merck, GSK, Pfizer, and Sanofi Pasteur. No other potential conflicts of interest were disclosed.

Références

J Am Soc Nephrol. 2020 Mar;31(3):625-636
pubmed: 31941721
Clin J Am Soc Nephrol. 2013 Dec;8(12):2149-57
pubmed: 24115195
Clin Kidney J. 2015 Dec;8(6):772-80
pubmed: 26613038
Clin Infect Dis. 2018 Sep 28;67(8):1175-1181
pubmed: 29659728
Kidney Int. 2005 Sep;68(3):914-24
pubmed: 16105022
Am J Kidney Dis. 2019 Jan;73(1):102-111
pubmed: 29661541
Clin Kidney J. 2017 Feb;10(1):55-61
pubmed: 28638604
Infect Control Hosp Epidemiol. 2016 Feb;37(2):205-7
pubmed: 26554448
Transplantation. 2013 Jan 27;95(2):309-18
pubmed: 23325005
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1402-9
pubmed: 24948142
JAMA Surg. 2015 Jun;150(6):529-36
pubmed: 25923973
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):262-274
pubmed: 33509963
Am J Nephrol. 2015;42(4):328-36
pubmed: 26569600
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1139-1146
pubmed: 28663227
Hemodial Int. 2014 Jan;18(1):118-26
pubmed: 24118883
Am J Kidney Dis. 2013 Apr;61(4 Suppl 2):S24-32
pubmed: 23507267

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH